Source - LSE Regulatory
RNS Number : 6424H
BSF Enterprise PLC
20 March 2024
 

20 March 2024

BSF Enterprise PLC

("BSF" or the "Company")

 

Result of Annual General Meeting

 

BSF Enterprise (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based tissue engineering company 3D Bio-Tissues Ltd (3DBT) and corneal tissue replacement company Kerato Ltd, is pleased to announce that at the Company's Annual General Meeting held earlier today, all resolutions proposed were duly passed by shareholders by way of a poll, the results of which were as follows:

 

Resolution

Poll Results

For

Against

Withheld

Discretionary

Total

1

Shares

52,426,227

-

-

-

52,426,227

%

100.00%

-

-

-

100%

2

Shares

52,421,227

5,000

-

-

52,426,227

%

99.99%

0.01%

-

-

100%

3

Shares

52,421,227

5,000

-

-

52,426,227

%

99.99%

0.01%

-

-

100%

4

Shares

52,426,227

-

-

-

52,426,227

%

100.00%

-


-

100%

5

Shares

46,646,377

-

5,779,850

-

52,426,227

%

88.98%

-

11.02%

-

100%

6

Shares

52,426,227

-

-

-

52,426,227

%

100.00%

-

-

-

100%

7

Shares

52,402,826

23,401

-

-

52,426,227

%

99.96%

0.04%

-

-

100%

8

Shares

52,421,227

-

5,000

-

52,426,227

%

99.99%

-

0.01%


100%

9

Shares

52,397,826

23,401

5,000

-

52,426,227

%

99.95%

0.04%

0.01%

-

100%

 

 

About BSF Enterprise PLC:

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cellbased tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas for testing to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality leather from its laboratory in Newcastle, transforming the leather industry towards an ethical and sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to develop a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

BSF Enterprise PLC

Via SEC Newgate below

Geoff Baker - Executive Director

Che Connon - CEO & Director

 


Shard Capital (Broker)


Damon Heath
Isabella Pierre

0207 186 9000

0207 186 9927

 

SEC Newgate (Financial Communications)


Bob Huxford

020 3757 6882

Elisabeth Cowell

BSF@secnewgate.co.uk

 

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

 



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGURVURSVUOUAR
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Bsf Enterprise PLC (BSFA)

0p (0.00%)
delayed 15:57PM